Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025

(MedPage Today) -- More debate about whether the lowest-risk prostate cancers should even be called "cancer." (Harvard Health Publishing)
Four cancer drugs -- palbociclib (Ibrance), enzalutamide (Xtandi), pomalidomide (Pomalyst), and acalabrutinib...